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The RRBS protocol combines DNA digestion with a methylationinsensitive restriction enzyme and size selection to select a reproducible subset of the genome 3, 4 . This 'reduced representation' is bisulfite-sequenced and its DNA methylation profile is compared for disease and control samples. To adapt the mouse RRBS protocol to human, we initially performed in silico digestions, confirming that MspI digestion and a size selection of 40-220 base pairs (bp) enriched for cytosine-phosphate-guanine (CpG) islands and promoter regions (data not shown). We tested this protocol on two fresh-frozen clinical samples: from a colon tumor and from adjacent normal tissue of the same individual. We obtained 8.7 and 5.3 million high-quality aligned reads, respectively, yielding DNA methylation data for more than 1 million unique CpG dinucleotides in each sample ( Table 1) . We obtained quantitative data with more than 25 individual CpG measurements (corresponding to the sum of high-quality sequencing coverage over all CpG dinucleotides in a region) for 65% of core promoters, 50% of CpG islands and 17% of putative regulatory elements ( Fig. 1a) . Furthermore, we observed coverage of a sizable number of CpG island 'shores' 9 , enhancers, exons, 3′ untranslated regions and repetitive elements (see http://rrbs-techdev.computationalepigenetics.org/). This constituted a slight improvement compared to previously reported RRBS data in mouse samples 4 .
Before analyzing human clinical samples, we optimized three aspects of the RRBS protocol. First, we minimized the input DNA requirement to be able to process minimal tissue samples and cell populations sorted by flow cytometry (Fig. 1b) . In two subsequent rounds of optimization we reduced the amount of input DNA from 1 µg to 300 ng and from 100 ng to 30 ng ( bisulfite sequencing measures absolute levels of dna methylation at single-nucleotide resolution, providing a robust platform for molecular diagnostics. We optimized bisulfite sequencing for genome-scale analysis of clinical samples: here we outline how restriction digestion targets bisulfite sequencing to hotspots of epigenetic regulation and describe a statistical method for assessing significance of altered dna methylation patterns. thirty nanograms of dna was sufficient for genome-scale analysis and our protocol worked well on formalin-fixed, paraffin-embedded samples.
The role of DNA methylation in human diseases has sparked interest in genome-scale methods for DNA methylation profiling 1 . Among an array of protocols for measuring DNA methylation, bisulfite sequencing stands out for its ability to quantify the DNA methylation status of essentially all nonrepetitive regions in the genome at single-nucleotide resolution 2 . We recently developed reduced representation bisulfite sequencing (RRBS) as an accurate yet cost-efficient method for genome-scale DNA methylation analysis 3, 4 . Here we show that RRBS is highly appropriate for DNA methylation profiling of human samples, for example, in the context of case-control studies investigating diseasespecific epigenome alterations. We address four obstacles that hamper epigenome mapping in clinical samples, namely high input DNA requirements, inability to analyze formalin-fixed, paraffinembedded (FFPE) samples, incomplete bisulfite conversion and lack of data-analysis tools. (i) Methods such as methylated DNA immunoprecipitation profiles generated using next-generation sequencing (MeDIP-seq) 5 , methyl-binding domain-sequencing rather than on human material to minimize the number of potential confounding factors. To confirm that the low-input protocol worked well for human disease samples, we performed RRBS on two human blood samples using 30 ng of input DNA and observed a correlation of 0.96 between the two samples ( Supplementary Table 1 ).
Second, we optimized RRBS analysis for DNA extracted from FFPE tissue slices. Focusing on two matched colon samples that have been stored in FFPE format since 2001, we observed the characteristic DNA degradation pattern of FFPE samples (Supplementary Fig. 1a ). To avoid degradation products in the selected size range (40-220 bp), we size-selected DNA fragments greater than 500 bp before digesting the genomic DNA with MspI. Our protocol resulted in high-quality RRBS libraries ( Supplementary Fig. 1b) , and the sequencing yield was comparable to that of fresh-frozen samples ( Table 1) . We also observed high overall agreement between the FFPE samples and the freshfrozen samples in terms of genomic coverage and DNA methylation measurements (Supplementary Fig. 2) . Specifically, the correlation of DNA methylation at CpGs with at least 25-fold sequencing coverage was 0.87 between the fresh-frozen and the FFPE colon tumor, and 0.88 between the fresh-frozen and the FFPE normal colon tissues ( Supplementary Table 1 ).
Third, we optimized bisulfite treatment to maximize conversion of unmethylated cytosines while minimizing loss of input DNA owing to bisulfite-induced degradation. Across multiple experiments in clinical samples and mouse ES cells, we found a conversion protocol with two subsequent 5-h bisulfite treatments 10 was more effective than our previously used single-step 14-h protocol (conversion rate >99% in all experiments). We also performed RRBS on in vitro-methylated and in vivo-demethylated DNA from a single cell line. This experiment confirmed that the overall amount of DNA methylation did not have a visible effect on the bisulfite conversion rate ( Table 1) . Finally, we compared the DNA sequence properties (sequence composition, structural features, repeat content and others) between the regions that exhibited comparatively low versus high bisulfite conversion, using the EpiGRAPH web service 11 . No consistent correlation with the bisulfite conversion rates could be identified (data not shown), suggesting that systematic bisulfite conversion bias is not a problem when applying RRBS to human disease samples.
As an additional validation, we analyzed DNA methylation of the fresh-frozen colon tumor sample using the Infinium HumanMethylation27 platform (Infinium), which combines bisulfite conversion with a genotyping microarray to measure DNA methylation in promoter regions 12 . For 1,027 CpGs both methods yielded high-confidence measurements, and we observed a correlation of 0.88 between Infinium and RRBS (Fig. 1c) . Furthermore, when we allowed for up to 100 bp distance between the CpGs assayed by Infinium and RRBS, the high-confidence overlap between both methods increased to 7,324 CpGs and the correlation between the two assays remained high (Pearson's r = 0.77). This observation is consistent with high autocorrelation of DNA methylation in the CpG-rich regions of the human genome 13, 14 and provides justification for measuring DNA methylation at a subset of indicator CpGs rather than at every single CpG within a given region.
To complement the experimental optimizations described above, we developed a bioinformatic data analysis pipeline to identify subtle alterations of DNA methylation in genomic regions with putative gene-regulatory potential (Supplementary Note). This pipeline builds on a comprehensive set of pre-annotated genomic regions (which includes promoters, CpG islands and many other genomic features). For each region it performs a statistical test for differential DNA methylation, and it calculates P values without having to introduce any arbitrary threshold parameters. Multiple-testing correction is performed by controlling the false discovery rate. Restricting the analysis to a relevant subset of the genome increases the statistical power for detecting subtle alterations in gene-regulatory regions because the P values are not diluted by multiple-testing correction for regions that are a priori unlikely to be differentially methylated.
To illustrate the features of the bioinformatic analysis pipeline, we compared the DNA methylation profile of the colon tumor with matched normal colon tissue. We observed tumor-specific hypermethylation at 52 gene promoters, 114 CpG islands and hundreds of additional genomic regions. Affected genes included SOX17 (Fig. 1d) and GATA5, which are known targets of hypermethylation in colon cancer 15, 16 . However, classical targets such as APC and MGMT were unmethylated in this particular tumor.
To corroborate the observation that few genes were hypermethylated in the tumor sample, we assessed whether the tumor classified as CpG island methylator phenotype (CIMP) based on a recently published biomarker 17 . CIMP is a characteristic property of a subset of colon cancers exhibiting widespread DNA methylation at many CpG island promoters. We inspected the promoters of five genes that have been identified as predictive of CIMP 17 , and the RRBS data clearly denoted the tumor as CIMP-negative. In addition to hypermethylation at a subset of gene promoters, we also observed cases of tumor-specific hypomethylation. An example is HNF4A (Fig. 1d) , a gene encoding a hepatic transcription factor that has an essential role in colon development 18 .
The RRBS method's deep coverage of gene promoters plus selective sampling of all other types of genomic regions makes it most useful for detecting new epigenetic alterations, for example, in the context of biomarker discovery 19 . Compared to truly genome-wide bisulfite sequencing, its focus on a reduced representation of the genome translates into a substantial cost advantage and the ability to screen more samples. In contrast, padlock-targeted bisulfite sequencing and epigenotyping microarrays currently achieve substantially lower genomic coverage, making these technologies more suitable for validating findings than for initial discovery. In terms of sample quality and input DNA requirements, RRBS is more forgiving than any other method for epigenome profiling that we are aware of. It is thus possible to run RRBS as an addon for essentially all ongoing tumor genomics initiatives and to generate genome-wide methylation profiles of some of the most interesting and best-annotated sample collections. Finally, with ever-decreasing sequencing costs, RRBS will readily scale to more comprehensive genomic coverage, for example, by using additional restriction enzymes or widening the size-selection window.
methods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemethods/.
Note: Supplementary information is available on the Nature Methods website.
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